Monoclonal antibodies that are effective against all COVID-19 -related viruses

Authors

DOI:

https://doi.org/10.25250/thescbr.brk779

Keywords:

COVID-19, antibodies, broaden immunity, vaccination strategy

Abstract

All licensed COVID-19 antibody treatments become ineffective over time as new mutants emerge. We isolated antibodies from an individual who recovered from SARS-1 and received the COVID vaccine, that work against all COVID-related viruses including the latest Omicron variants. These broad-targeting antibodies could make future-proof therapeutics to counter the continual evolution of coronaviruses.

Author Biography

Wan Ni Chia, Duke-NUS Medical School

Senior Research Fellow

Original article reference

Chia, W. N., Tan, C. W., Tan, A. W. K., Young, B., Starr, T. N., Lopez, E., Fibriansah, G., Barr, J., Cheng, S., Yeoh, A. Y.-Y., Yap, W. C., Lim, B. L., Ng, T.-S., Sia, W. R., Zhu, F., Chen, S., Zhang, J., Kwek, M. S. S., Greaney, A. J., … Wang, L.-F. (2023). Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor. Science Advances, 9(30). https://doi.org/10.1126/sciadv.ade3470

Downloads

  • URL

Published

2024-01-31

Issue

Vol. 10 No. 1 (2024): TheScienceBreaker

Section

Microbiology

License

Some rights reserved 2023 Wan Ni Chia

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.